AU Patent

AU2020260492A1 — Improved compositions for treating muscular dystrophy

Assigned to Sarepta Therapeutics Inc · Expires 2020-11-26 · 5y expired

What this patent protects

DCC-28/10/2020 ABSTRACT Improved compositions and methods for treating muscular dystrophy by administering an antisense molecule such as eteplirsen, capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, are described.

USPTO Abstract

DCC-28/10/2020 ABSTRACT Improved compositions and methods for treating muscular dystrophy by administering an antisense molecule such as eteplirsen, capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, are described.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020260492A1
Jurisdiction
AU
Classification
—
Expires
2020-11-26
Drug substance claim
No
Drug product claim
No
Assignee
Sarepta Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.